A Phase 2 interventional study of Pemigatinib and Retifanlimab in Advanced Malignancies, sponsored by Incyte Corporation. Terminated at 10 sites in 4 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.
A Phase 2 Open-Label, Multicenter, Rollover Study to evaluate the long term safety and tolerability of Pemigatinib and to provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pemigatinib will be taken orally once daily
Drug: Pemigatinib
Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and retifanlimab will be administered once every 4 weeks
Drug: Pemigatinib · Drug: Retifanlimab
Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and pembroluzimab as per dosage instructions.
Drug: Pemigatinib · Drug: Pembrolizumab
Pemigatinib tablets taken by mouth once daily as per protocol
Also known as: INCB054828
Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)
Also known as: INCMGA0012
Commercially labeled products
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. TEAEs were defined as AEs either reported for the first time or the worsening of pre-existing events after the first dose of study drug and until 30 days after the last dose of study drug.
Time frame: up to at least 30 days after the last dose of study treatment or until toxicities resolve, return to baseline, or are deemed irreversible, whichever was longer (up to 1010 days)
Participants who were actively receiving treatment with pemigatinib (monotherapy or in combination with pembrolizumab) under a parent protocol, were receiving clinical benefit in those trials, and who did not have access to pemigatinib (as monotherapy or as combination therapy) outside of a clinical trial were enrolled.
| Milestone | Pemigatinib 6 mg Monotherapy | Pemigatinib 9 mg Monotherapy | Pemigatinib 13.5 mg Monotherapy | Pemigatinib Combination |
|---|---|---|---|---|
| Started | 2 | 5 | 2 | 1 |
| Completed | 1 | 3 | 1 | 0 |
| Not completed | 1 | 2 | 1 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 1 | 0 | 0 |
| Withdrew: Transitioned to commercial pemigatinib | 0 | 1 | 0 | 0 |
| Withdrew: Sponsor terminated study | 0 | 0 | 1 | 1 |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. TEAEs were defined as AEs either reported for the first time or the worsening of pre-existing events after the first dose of study drug and until 30 days after the last dose of study drug.
| Participants | Pemigatinib 6 mg Monotherapy | Pemigatinib 9 mg Monotherapy | Pemigatinib 13.5 mg Monotherapy | Pemigatinib Combination |
|---|---|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 1 | 5 | 1 | 1 |
Collected over up to 1010 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemigatinib 6 mg Monotherapy | 0/2 (0%) | 1/2 (50%) | 1/2 (50%) |
| Pemigatinib 9 mg Monotherapy | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Pemigatinib 13.5 mg Monotherapy | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Pemigatinib Combination | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Pemigatinib 6 mg Monotherapy | Pemigatinib 9 mg Monotherapy | Pemigatinib 13.5 mg Monotherapy | Pemigatinib Combination |
|---|---|---|---|---|
| Cardiac failureCardiac disorders | 1/2 | 0/5 | 0/2 | 0/1 |
| Acute kidney injuryRenal and urinary disorders | 0/2 | 1/5 | 0/2 | 0/1 |
| SeizureNervous system disorders | 0/2 | 1/5 | 0/2 | 0/1 |
| Event | Pemigatinib 6 mg Monotherapy | Pemigatinib 9 mg Monotherapy | Pemigatinib 13.5 mg Monotherapy | Pemigatinib Combination |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/2 | 1/5 | 0/2 | 1/1 |
| HaematuriaRenal and urinary disorders | 0/2 | 0/5 | 0/2 | 1/1 |
| Joint swellingMusculoskeletal and connective tissue disorders | 0/2 | 0/5 | 0/2 | 1/1 |
| StomatitisGastrointestinal disorders | 1/2 | 4/5 | 0/2 | 1/1 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/2 | 0/5 | 0/2 | 1/1 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 1/2 | 4/5 | 0/2 | 0/1 |
| Blood creatinine increasedInvestigations | 1/2 | 0/5 | 0/2 | 0/1 |
| Drug hypersensitivityImmune system disorders | 0/2 | 0/5 | 1/2 | 0/1 |
| Multiple allergiesImmune system disorders | 0/2 | 0/5 | 1/2 | 0/1 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/2 | 0/5 | 1/2 | 0/1 |
The 6 mg (n=2) and 13.5 mg (n=2) monotherapy groups have been combined into a single arm retain participant privacy and reduce the risk of participant re-identification.
| Age, Continuous(years) | Pemigatinib 6 mg and 13.5 mg Monotherapy | Pemigatinib 9 mg Monotherapy | Pemigatinib Combination | Total |
|---|---|---|---|---|
| Mean | 64.5 ± 17.20 | 61.2 ± 6.30 | NA ± NA | NA ± NA |
| Sex: Female, Male(Participants) | Pemigatinib 6 mg and 13.5 mg Monotherapy | Pemigatinib 9 mg Monotherapy | Pemigatinib Combination | Total |
|---|---|---|---|---|
| Female | 2 | 2 | NA | NA |
| Male | 2 | 3 | NA | NA |
| Ethnicity (NIH/OMB)(Participants) | Pemigatinib 6 mg and 13.5 mg Monotherapy | Pemigatinib 9 mg Monotherapy | Pemigatinib Combination | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | NA | NA |
| Not Hispanic or Latino | 4 | 5 | NA | NA |
| Unknown or Not Reported | 0 | 0 | NA | NA |
| Race/Ethnicity, Customized(Participants) | Pemigatinib 6 mg and 13.5 mg Monotherapy | Pemigatinib 9 mg Monotherapy | Pemigatinib Combination | Total |
|---|---|---|---|---|
| White/Caucasian | 2 | 4 | NA | NA |
| Asian | 1 | 1 | NA | NA |
| Black/African-American | 1 | 0 | NA | NA |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2021 to primary completion in Apr 2024, 33 months.
Results were first posted in Sep 2024, 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemigatinib